Obesity and the heart: “Dangerous Liaisons”

Obesity is the epidemic of the 21st century, with a high impact on global health, and on cardiovascular health in particular, being simultaneously an independent cardiovascular risk factor and being in the etiopathogenesis of other risk factors, namely diabetes. The development of new drugs with proven efficacy in its treatment, such as GLP1 agonists, and dual GLP1 and GIP agonists, with a significant impact on cardiovascular, renal, and other diseases, constitutes a true revolution in the treatment of patients with obesity and cardiovascular disease (CVD). The emergence of the new concept of cardio-renal-metabolic syndrome, in which the presence of excess and/or dysfunctional adipose tissue translates into a set of pathophysiological mechanisms that lead to the development of cardiac, renal, and metabolic diseases, is relatively recent. However, it reflects an increasingly present reality in obese patients, where the coexistence of these pathologies represents a significant worsening of the prognosis and greater difficulty in their management. Given the challenges in prevention, diagnosis, and treatment that patients with adiposopathy and CVD represent, it is clearly beneficial that their approach be carried out by multidisciplinary teams in order to effectively respond to the multiple challenges that this pathology currently presents.